In Vivo Model Systems in P-Glycoprotein-Mediated Multidrug Resistance
Authors:
- 1 January 1998
- journal article
- research article
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 35 (1) , 1-57
Abstract
In this article we review the in vivo model systems that have been developed for studying P-glycoprotein-mediated multidrug resistance (MDR) in the preclinical setting. Rodents have two mdr genes, both of which confer the MDR phenotype: mdr1a and mdr1b. At gene level they show strong homology to the human MDR1 gene and the tissue distribution of their gene product is very similar to P-glycoprotein expression in humans. In vivo studies have shown the physiological roles of P-glycoprotein, including protection of the organism from damage by xenobiotics. Tumors with intrinsic P-glycoprotein expression, induced MDR or transfected with an mdr gene, can be used as sy ngeneic or xenogenic tumor models. Ascites, leukemia, and solid MDR tumor models have been developed. Molecular engineering has resulted in transgenic mice that express the human MDR1 gene in their bone marrow and in knockout mice missing a murine mdr gene. The data on pharmacokinetics, efficacy, and toxicity of chemosensitizers of P-glycoprotein in vivo are described. Results from studies using monoclonal antibodies directed against P-glycoprotein and other miscellaneous approaches for modulation of MDR are mentioned. The importance of in vivo studies prior to clinical trials is being stressed and potential pitfalls due to differences between species are discussed.Keywords
This publication has 180 references indexed in Scilit:
- Transfer of the MDR1 gene into haematopoietic cellsEuropean Journal of Cancer, 1996
- Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignanciesEuropean Journal of Cancer, 1996
- Clinical trials of p-glycoprotein reversal in solid tumoursEuropean Journal of Cancer, 1996
- What have we learnt thus far from mice with disrupted P-glycoprotein genes?European Journal of Cancer, 1996
- Pharmacological considerations in the modulation of multidrug resistanceEuropean Journal of Cancer, 1996
- MDR1 gene expression in solid tumoursEuropean Journal of Cancer, 1996
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisersEuropean Journal of Cancer, 1996
- How to probe clinical tumour samples for p-glycoprotein and multidrug resistance-associated proteinEuropean Journal of Cancer, 1996
- Adding a Reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenograftsEuropean Journal of Cancer, 1995
- In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumourJournal of Cancer Research and Clinical Oncology, 1993